Anti-bird flu new drugs put into operation there is no timetable

Published: 2013 05 01 at 14:57

Reporters from the Hunan Nonferrous Chembrane Bio-Pharmaceutical Co., Ltd. was informed that, in early April the company approved anti-bird flu drug peramivir has passed the GMP (Good Manufacturing quality standards) certification, but there is no production schedule. Early last month, in response to human infection with the H7N9 avian flu, the State Food and Drug Administration and the Drug Evaluation Center rapid deployment and approved by China's independent research and development of new drugs to market peramivir. In accordance with the relevant procedures, peramivir passed GMP certification, can be put into production. However the Hunan Nonferrous Chembrane responsible for people, told reporters that peramivir exactly when production is planned to study and then set according to market conditions.

http://translate.googleusercontent.com/translate_c?depth=1&hl=en&prev=/search%3Fq%3DH7N9%26start%3D20%26lr%3D%26sa%3DN%26hl%3Den%26noj%3D1%26biw%3D1071%26bih%3D769%26tbs%3Dqdr:h&rurl=translate.google.com&sl=zh-TW&u=http://big5.xinhuanet.com/gate/big5/m.news.cn/entityitem/1907/20130501/3944094_1_x_.shtml&usg=ALkJrhjutjEm1DM0DLdAf-nvnti40-nQ9g